Greenwich LifeSciences Finalizes Dual Audit, Reports $10.5M Cash and 70–80% Recurrence Drop
GLSI•Greenwich LifeSciences said its 2025 Form 10-K is in final dual-audit approval after large accounts payable adjustments from FLAMINGO-01 screening and reports unaudited cash of $10.5M, above its $9.9M net cash used. Preliminary open-label non-HLA-A*02 data shows 70–80% drop in breast cancer recurrences after primary immunization series.
1. Form 10-K Filing Status
Greenwich LifeSciences’ 2025 Form 10-K remains under dual-auditor review due to significant accounts payable adjustments driven by higher FLAMINGO-01 trial screening and enrollment. Both the new and prior auditors must agree on adjustments related to increased Europe patient screening before the filing receives final approval.
2. Financial Position and Cash Balance
The company reports an unaudited ending cash balance of $10.5 million as of March 31, 2026, which exceeds the $9.9 million net cash used in operating activities for fiscal 2025. Improved accounts payable estimates based on current clinical trial data have strengthened financial forecasting for upcoming Form 10-Q filings.
3. Early FLAMINGO-01 Non-HLA-A*02 Data
In the open-label non-HLA-A*02 arm of FLAMINGO-01, more than 250 patients have received GLSI-100 and preliminary analysis shows a 70–80% reduction in breast cancer recurrence rates after the six-month primary immunization series. These early results align with prior Phase IIb findings and support continued enrollment and data review.
